Scholar Rock Holding (SRRK) Operating Income (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Operating Income came in at -$102.0 million in Q1 2026, down 32.33% year-on-year from -$150.8 million in Q1 2025, and down 11.01% quarter-over-quarter from -$91.9 million in Q4 2025.
Scholar Rock Holding (SRRK) Operating Income (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Operating Income history runs 10 years deep, the most recent figure standing at -$102.0 million for Q1 2026.
- On a quarterly basis, Operating Income fell 32.33% year-over-year to -$102.0 million in Q1 2026; TTM through Mar 2026 was -$409.6 million, a 51.29% decrease from a year earlier, with the FY2025 full-year figure at -$384.6 million, down 52.6% from the prior year.
- Operating Income retreated to -$102.0 million in Q1 2026 per SRRK's latest filing, from -$91.9 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.9 million in Q1 2022 and bottomed at -$112.1 million in Q2 2025.
- The 5-year median for Operating Income is -$58.4 million (2024), against an average of -$61.4 million.
- Across the five-year window, Operating Income jumped 74.52% in 2022 and sank 484.29% in 2023, its largest moves.
- Year by year, Operating Income stood at -$40.4 million in 2022, then fell by 18.81% to -$48.0 million in 2023, then sank by 44.4% to -$69.4 million in 2024, then sank by 32.5% to -$91.9 million in 2025, then slipped by 11.01% to -$102.0 million in 2026.
- Per Business Quant, the three latest SRRK Operating Income figures stand at -$102.0 million (Q1 2026), -$91.9 million (Q4 2025), and -$103.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Scholar Rock Holding | 6.10 Bn | 6.10 Bn | - | -102.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.02 Mn |
| Dec 31, 2025 | -91.90 Mn |
| Sep 30, 2025 | -103.55 Mn |
| Jun 30, 2025 | -112.11 Mn |
| Mar 31, 2025 | -77.09 Mn |
| Dec 31, 2024 | -69.36 Mn |
| Sep 30, 2024 | -64.78 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Mar 31, 2024 | -58.42 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |
| Jun 30, 2021 | -30.27 Mn |